Purpose: We aimed to evaluate the added value of performing fourth and subsequent follow-up 18 F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma. Methods: This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18 F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18 F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival. Results: Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions: The fourth and subsequent 18 F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.
T he American Cancer Society has estimated that 73,870 new cases of invasive melanoma will be diagnosed in 2015. 1 Although melanoma accounts for less than 2% of all skin cancer cases, approximately 75% of all skin cancer deaths are from melanoma. The 5-year survival rate for patients with treated localized melanoma is 98%, decreasing to 63% when locoregional spread is diagnosed and to 16% when the patient developed distant metastases. 1 Late recurrence of melanoma is also common, with approximately 6.9% of cases demonstrating recurrence 10 or more years after initial treatment. 2 The National Comprehensive Cancer Network guidelines for melanoma (version 3.2015) state that chest x-ray, CT, and/or PET/CT every 4 to 12 months and annual brain MRI can be considered to screen high-risk patients for recurrent or metastatic disease at the discretion of the physician (category 2B), but follow-up imaging is not recommended beyond 5 years. [3] [4] [5] [6] [7] In recent years, 18 F-FDG PET/CT has gained special importance in many oncology patients for staging, therapy assessment, management, and prognosis. [8] [9] [10] [11] [12] For the follow-up of patients with melanoma, 18 F-FDG PET/CT has been shown to have an impact in patient's management and in predicting prognosis. [13] [14] [15] [16] The Centers for Medicare & Medicaid Services had recently made a decision that 3 posttreatment follow-up 18 F-FDG PET/CT scans are covered under §1862 (a)(1)(A) when used to guide subsequent management of antitumor treatment strategy after completion of initial anticancer therapy for 1 tumor type, per patient; therefore, coverage for any additional follow-up 18 F-FDG PET/CT scans beyond 3 will be funded at the discretion of the local Medicare Administrative Contractors, 17 justified by medical necessity.
We have previously published that performing a fourth and subsequent follow-up 18 F-FDG PET/CT added value to clinical decision and patient's management, in appropriate clinical setting, and were prognostic markers for overall survival (OS) in lung and colorectal cancers. 18, 19 The objective of this study was to establish the value of fourth and subsequent posttherapy follow-up 18 F-FDG PET/CT scans in the management of patients with melanoma.
MATERIALS AND METHODS

Eligible Patients and Follow-up
This was an institutional review board-approved, retrospective study performed under a waiver of informed consent. The guidelines of the Health Insurance and Portability and Accountability Act were followed. Patients with biopsy-proven melanoma were followed up with 18 F-FDG PET/CT scan after completion of primary treatment. Patients with concurrent primary tumors or a second primary cancer were excluded. We evaluated a total of 232 patients, with biopsy-proven melanoma who had an 18 F-FDG PET/CT scan between January 2000 and June 2012. Among these, we identified 71 patients (30.6%) who had 4 or more 18 F-FDG PET/CT scans as part of their follow-up, providing a total of 246 fourth and subsequent follow-up PET/CT scans (range, 4-18 follow-up PET/CT scans per patient). Only the fourth and subsequent follow-up PET/CT scans were included in this study. The scans were acquired either (a) with prior clinical signs suggestive of disease, as patients demonstrated signs or symptoms or other clinical evidence of recurrence or metastasis or for secondary therapy assessment or (b) without prior clinical suspicion but imaged as part of follow-up clinical office visits. Patients were followed up with a median follow-up period of 93 ± 27.1 months from the fourth follow-up PET/CT scan. Patients who were alive were censored at the last date of follow-up, whereas the date of death was used for the patients who died.
Image Analysis
18
F-FDG PET/CT images were interpreted by board-certified nuclear medicine physicians as per routine imaging review protocol in our institution. Using the electronic clinical patients' records, the PET/CT scan reports were retrospectively categorized as positive or negative by a nuclear medicine physician. Positive reports clearly identified possible sites of disease recurrence or metastases related to the primary melanoma, whereas negative reports clearly excluded the possibility of malignancy. For analysis purposes, indeterminate scans were categorized as negative for disease recurrence or metastasis. The scans were also dichotomized according to pretest clinical signs suggestive of recurrence or metastases, which was established from the clinical note prior to the PET/CT scan of the clinician requesting the scan and from the scan request's indication.
Assessment of Patient Management
Patient's electronic medical records were used to collect patient's treatment details before and after each PET/CT scan and to establish the change in patient's management. The impact of each of the 18 F-FDG PET/CT follow-up scan results on the patient's treatment strategy was assessed. We dichotomized patients as whether they were on treatment or followed up without treatment before the PET/CT scan. We further established whether patients continued with the same ongoing treatment or started a new treatment or discontinued treatment or continued follow-up without treatment, after each PET/CT scan. Outcome measure, OS, was defined as the time (in months) interval between the date of the fourth or subsequent follow-up PET/CT scan and the date of death, which was extracted from a review of medical records and a public registry of death, last reviewed in August 2015 (www.ancestry.com). The survival data for patients who were alive were censored at the last follow-up date at our institution.
Statistical Analysis
This study focused on the impact of performing fourth and subsequent follow-up 18 F-FDG PET/CT scans in melanoma treatment management, and the relationship between these PET/CT results and patient's OS. Descriptive features of variables were presented as mean ± SD. A χ 2 analysis was performed to evaluate the impact of scan results (positive or negative) on treatment of melanoma using 6 classified categories. Kaplan-Meier survival curves were plotted based on the PET/CT results analyzing the 
Categorization of PET/CT Results
We categorized the fourth or consecutive follow-up PET/CT scans as "negative" or "positive" for recurrence, residual tumor, or metastases. Approximately 60.9% (150/246) of the scans were negative for malignancy, and the remainder 39.0% of the scans (96/246) were positive for malignancy. Nine scans (3.6%) were interpreted as indeterminate for malignancy, and for clinical utility purposes, these indeterminate scans were grouped together with the negative scans. Among the 96 positive PET/CT scans, 85.4% (82/96) of the scans were positive for distant metastatic disease, whereas 14.6% (14/96) scans were reported as positive for locoregional tumor recurrence. Most of the scans, 83.3% (205/246) were performed more than 24 months after completion of primary treatment, whereas 16.7% (41/246) were performed within 24 months from the primary treatment.
Impact on Clinical Assessment
We evaluated the impact of 18 F-FDG PET/CT on clinical assessment in the follow-up period at the time of the scan. Of the 246 scans, 123 (50.0%) were obtained for follow-up without prior clinical signs suggestive of disease, and 123 (50.0%) were obtained with prior suspicion of malignancy or for therapy assessment of secondary treatments. In the context of clinical assessment, PET/ CT identified recurrence or metastasis in 6.5% (8/123) of scans obtained without prior clinical suspicion and ruled out malignancy in 28.5% (35/123) of scans obtained with prior clinical signs suggestive of disease or for therapy assessment of secondary treatments. Figure 1 summarizes the PET/CT scan results according to clinical suspicion. Of note, among the 123 scans obtained with prior clinical signs suggestive of disease or for therapy assessment, 93% had prior known metastatic lesions: 105 of the scans (85.4%) were performed during midtreatment, 9 scans (7.3%) soon after completion of a treatment, and 9 scans (7.3%) were performed while the patient was on no treatment.
We also compared the impact of the fourth or subsequent PET scans in the patient's management with regard to the results of the first 3 PET scans. Among 30 patients with 3 prior negative scans, 5 of them had a positive fourth or subsequent PET scans, all proven by pathology, and treatment was initiated in all 5 patients. Among the 31 patients who had at least 1 of the 3 prior PET scans positive, and at least one-fourth or subsequent PET scan positive, treatment was changed in 20 of the 31 patients. The remainder 10 patients had all negative fourth or subsequent PET scans.
Impact on Change in Management Strategy
A careful review of the patient's electronic medical records was used to assess the impact of each of the fourth and subsequent follow-up PET/CT scans on the treatment planning in the context of clinical suspicion or therapy response assessment.
For those scans performed with clinical suspicion or for therapy response assessment (123/246), changes in patient management occurred in 29.3% (36/123) of scans. Changes in management included either starting a new treatment when the patient received no treatment before the scan (2/123), change in the treatment modality (33/123), or discontinuation of the treatment because of complete therapy response (1/123) (Fig. 2) . There is no change in management in remainder 70.7% (87/123) of the scans.
For the scans performed without prior clinical signs suggestive of malignancy (123/246) or for therapy response assessment, 4.1% (5/123) led to a change in the treatment management including starting new treatment (n = 4) and changing the treatment regimen (n = 1); examples are seen in Figures 3  and 4 . The patient's management was not changed in 95.9% (118/123) of scans that were obtained without prior clinical suspicion. Figure 5 summarizes the scans that were performed with and without clinical signs suggestive of malignancy, and in regard to the patient's management. Hence, change in management was significantly higher in patients with prior clinical signs suggestive of recurrence or metastases and for therapy assessment than without any clinical suspicion (29.3% vs 4.1%) (P < 0.0001).
PET/CT Results and Kaplan-Meier Survival Analysis
Of the 71 patients included in the study, 17 patients died during the study period, all of whom had at least 1 positive PET/CT scan. The Kaplan-Meier analyses based on the PET/CT scan results showed that there was significant difference in OS between patients who had at least one positive PET/CT scan (median OS, 28 ± 25.6 months) and those who had all negative fourth or subsequent PET/CT scans (median OS, 44.3 ± 24.9 months; HR, 5.3; 95% CI, 2.1-13.2) (Fig. 6 ). The univariate Cox regression analysis also revealed that the clinical suspicion prior to the scan could significantly predict the survival (HR, 11.7; 95% CI, 3.4-40.8; log-rank P < 0.001). In multivariate analysis, positive PET/CT scans did not remain statistically significant after adjustment for clinical suspicion (P = 0.954).
DISCUSSION
Our study aimed to evaluate the value of the fourth and subsequent 18 F-FDG PET/CT scans in the follow-up of patients with melanoma, performed after the completion of the primary treatment with or without clinical signs suggestive of disease recurrence or metastases. Our study revealed that the performance of a fourth and subsequent 18 F-FDG PET/CT scans can affect the therapy strategy, resulting in a change in patient's management plan in approximately 16.7% of the patients. Change in management was significantly more in patients with prior clinical signs suggestive of recurrence or metastases than without clinical suspicion (29.3% vs 4.1%). Furthermore, OS between patients with at least 1 of the fourth or subsequent positive PET/CT scans and those with all negative fourth or subsequent PET/CT scans differed significantly (median OS, 28 ± 25.6 vs 44.3 ± 24.9 months).
Existing literature have shown that approximately 80% of the melanoma recurrences occur within the first 3 years of diagnosis 20 ; however, these patients have a lifelong risk of relapse, and late recurrence, 10 or more years after initial treatment had been reported. 2, 21 DiFronzo et al 22 prospectively studied patients with American Joint Committee on Cancer stage I or II melanoma, concluding that patients with a diagnosis of cutaneous melanoma should undergo lifelong follow-up at biannual intervals to allow for earlier diagnosis and improved survival. However, no direct data had supported 1 interval schedule over another. In our study patients who had the first 3 PET/CT scans negative for malignancy, 16.6% of them developed locoregional or distant metastases in the fourth or subsequent follow-up PET/CT scans, which were performed with a median of 40.6 ± 7.9 months (range, 34-54 months) after completion of therapy. We believe PET scan timing after completion of primary treatment is irrelevant in decision making on whether to perform a PET/ CT scan; this decision should be taken in the context of a patient's clinical presentation and the level of the clinician's suspicion for recurrence or metastasis or for therapy response assessment.
A meta-analysis by Krug et al 14 analyzed the value of follow-up 18 F-FDG PET/CT in the management of high-risk American Joint Committee on Cancer stages III and IV melanoma patients after primary treatment, with suspicious pulmonary metastases. Follow-up PET/CT scans were reported to be associated with 15% to 64% of changes in the patient's management strategies. Similarly, Gulec et al 23 studied 49 patients with known or suspected metastases who underwent 18 F-FDG PET scan after initial treatment planning and found that PET findings led to changes in clinical management of 24 patients (49%). 23 Our findings are in the same direction but with lesser magnitude. Our study confirms the significant value of fourth or follow-up PET/CT when performed with prior clinical suspicion or as a therapy response monitoring in patients with metastatic disease.
Limited studies investigated the effectiveness of 18 F-FDG PET/CT in detecting recurrence in asymptomatic melanoma patients. In a recent study, Baker et al 24 reported that 18 F-FDG PET/ CT detected asymptomatic metastatic disease in only 5.3% of patients who were disease-free at 1 or more years after treatment and that more than 50% of the disease recurrences were identified first by either the patient or the physician on the basis of symptoms or serum markers. Our study results are consistent with this study, with only 5% management change in scans that were performed without prior clinical suspicion. This evidence suggests that performing 18 F-FDG PET/CT scans has low yield in asymptomatic and low-risk populations with melanoma and should be avoided.
The value of 18 F-FDG PET/CT in predicting survival in patients with melanoma has been previously reported. Niebling et al 25 studied the clinical outcome of 252 patients with stage III melanoma and clinical signs suggestive of recurrence, concluding that the 5-year survival rate was significantly higher in patients with a negative 18 F-FDG PET/CT scan than in patients with a positive scan (47.6 vs 16.9 %, P < 0.001). Our study further supports the association between OS and fourth and subsequent follow-up 18 F-FDG PET/CT scans as a prognostic marker. However, when adjusted for clinical suspicion, PET/CT result did not remain statistically significant for prediction of OS.
We acknowledge limitations of our study. The study was retrospective, which may have the possibility of inherent errors of confounding bias when the exposure is not controlled, and the results and conclusion should be interpreted with caution. The clinical indication of the study was retrospectively examined from electronic medical records and the PET/CT requisitions. The exact perspective of the clinician ordering the study was not collected prospectively, and we may have underestimated the clinical suspicion before the scans, which may have overestimated the number of studies classified as routine follow-up scans. Besides, indeterminate scan results were included in the study and grouped as negative, although the exact cause of such a result was not evaluated. The survival data were obtained from a public registry and from the patients' records at our institution; there may be a time lag between death and the public registry update.
